Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases

Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases Cardiol Ther (2016) 5:75–82 DOI 10.1007/s40119-016-0059-1 ORIGINAL RESEARCH Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases . . . Luis Rodrı´guez Padial Gonzalo Baro´n-Esquivias Antonio Herna´ndez Madrid . . Domingo Marzal Martı´n Vicente Pallare´s-Carratala´ Alejandro de la Sierra Received: February 10, 2016 / Published online: March 25, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com Abstract: Cardiovascular diseases are the Diltiazem, a non-dihydropyridine calcium leading cause of death in the world. Coronary channel blocker, is an effective and safe artery diseases, atrial fibrillation or hypertensive antihypertensive drug, alone or in combination heart disease, are among the most important with other agents. Diltiazem lowers myocardial cardiovascular disorders. Hypertension oxygen demand through a reduction in heart represents a significant risk factor for rate, blood pressure, and cardiac contractility, cardiovascular mortality; thus, control of high representing also a good alternative for the blood pressure has become a priority to prevent treatment of stable chronic angina. major complications. Although the choice of Furthermore, diltiazem reduces conduction in drugs for treating hypertension remains atrioventricular node, which is also useful for controversial, extensive clinical evidences point heart rate control in patients with atrial to calcium channel blockers as http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Loading next page...
 
/lp/springer-journals/clinical-experience-with-diltiazem-in-the-treatment-of-cardiovascular-0TAYwH7NUh

References (28)

Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Cardiology
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-016-0059-1
pmid
27016085
Publisher site
See Article on Publisher Site

Abstract

Cardiol Ther (2016) 5:75–82 DOI 10.1007/s40119-016-0059-1 ORIGINAL RESEARCH Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases . . . Luis Rodrı´guez Padial Gonzalo Baro´n-Esquivias Antonio Herna´ndez Madrid . . Domingo Marzal Martı´n Vicente Pallare´s-Carratala´ Alejandro de la Sierra Received: February 10, 2016 / Published online: March 25, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com Abstract: Cardiovascular diseases are the Diltiazem, a non-dihydropyridine calcium leading cause of death in the world. Coronary channel blocker, is an effective and safe artery diseases, atrial fibrillation or hypertensive antihypertensive drug, alone or in combination heart disease, are among the most important with other agents. Diltiazem lowers myocardial cardiovascular disorders. Hypertension oxygen demand through a reduction in heart represents a significant risk factor for rate, blood pressure, and cardiac contractility, cardiovascular mortality; thus, control of high representing also a good alternative for the blood pressure has become a priority to prevent treatment of stable chronic angina. major complications. Although the choice of Furthermore, diltiazem reduces conduction in drugs for treating hypertension remains atrioventricular node, which is also useful for controversial, extensive clinical evidences point heart rate control in patients with atrial to calcium channel blockers as

Journal

Cardiology and TherapySpringer Journals

Published: Mar 25, 2016

There are no references for this article.